Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO

MT Newswires Live

2024-11-20

Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.

The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.

Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.

The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.

Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan (HK), Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Hong Kong King-Friend Industrial, Alibaba Health (HKG:0241) subsidiary Alibaba Health (Hong Kong) Technology, Jointown Pharmaceutical (SHA:600998) subsidiary Jointown International Group, shareholder Wu Qiyuan, and Delta Capital Hong Kong, as cornerstone investors.

Huatai Financial Holdings (Hong Kong), CLSA, CMB International Capital, Ruibang Securities, and Patrons Securities, are the joint bookrunners and lead managers of the IPO.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2484186420"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484186420\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484186420?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 08:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484186420","market":"fut","top_or_hot":-1,"title":"Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.</p><p>The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.</p><p>Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.</p><p>The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.</p><p>Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan (HK), Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Hong Kong King-Friend Industrial, Alibaba Health (HKG:0241) subsidiary Alibaba Health (Hong Kong) Technology, Jointown Pharmaceutical (SHA:600998) subsidiary Jointown International Group, shareholder Wu Qiyuan, and Delta Capital Hong Kong, as cornerstone investors.</p><p>Huatai Financial Holdings (Hong Kong), CLSA, CMB International Capital, Ruibang Securities, and Patrons Securities, are the joint bookrunners and lead managers of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-11-20 08:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.</p><p>The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.</p><p>Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.</p><p>The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.</p><p>Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan (HK), Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Hong Kong King-Friend Industrial, Alibaba Health (HKG:0241) subsidiary Alibaba Health (Hong Kong) Technology, Jointown Pharmaceutical (SHA:600998) subsidiary Jointown International Group, shareholder Wu Qiyuan, and Delta Capital Hong Kong, as cornerstone investors.</p><p>Huatai Financial Holdings (Hong Kong), CLSA, CMB International Capital, Ruibang Securities, and Patrons Securities, are the joint bookrunners and lead managers of the IPO.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484186420","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484186420","pubTimestamp":1732062718,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hangzhou Jiuyuan Gene Engineering  launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan , Shanghai Fosun Pharmaceutical  subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical  subsidiary Hong Kong King-Friend Industrial, Alibaba Health  subsidiary Al","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"杭州九源基因工程最多5.7亿港元香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"89988":0.6,"600196":0.9,"600998":0.9,"603707":0.9,"00241":0.9,"02196":0.9,"HBBD.SI":0.6},"content_text":"Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan (HK), Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Hong Kong King-Friend Industrial, Alibaba Health (HKG:0241) subsidiary Alibaba Health (Hong Kong) Technology, Jointown Pharmaceutical (SHA:600998) subsidiary Jointown International Group, shareholder Wu Qiyuan, and Delta Capital Hong Kong, as cornerstone investors.Huatai Financial Holdings (Hong Kong), CLSA, CMB International Capital, Ruibang Securities, and Patrons Securities, are the joint bookrunners and lead managers of the IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0}}}